Commonwealth Coat of Arms of Australia

 

 

 

 

 

 

PB 33 of 2025

 

National Health (Originator Brand) Amendment Determination (No. 2) 2025

 I, Rebecca Richardson, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated                 27 March 2025  

REBECCA RICHARDSON

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care


1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1—Amendments

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)

 

 

  This instrument is the National Health (Originator Brand) Amendment Determination (No. 2) 2025.

  This instrument may also be cited as PB 33 of 2025.

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

 1 April 2025

 

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

  This instrument is made under subsection 99ADB(6B) of the National Health Act 1953.

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

1  Schedule 1, (after table item 206)

 

Insert:

 

206A

Sacubitril with valsartan

Entresto

 

 

 

2  Schedule 1, (after table item 228A)

 

Repeal:

229

Tirofiban

Aggrastat

 

 

229A

Tobramycin

DBL Tobramycin

Pfizer Australia Pty Ltd

Injection

 

Tobi

Inhalation

 

TOBI podhaler

Inhalation by mouth

 

Tobrex

Application to the eye

 

229B

Tocilizumab

Actemra

Actemra ACTPen

Actemra Subcutaneous Injection

 

 

 

Substitute:

 

229

Tirofiban

Aggrastat

 

 

229A

Tobramycin

DBL Tobramycin

Pfizer Australia Pty Ltd

Injection

 

Tobi

Inhalation

 

TOBI podhaler

Inhalation by mouth

 

Tobrex

Application to the eye

 

229B

Tocilizumab

Actemra

Actemra ACTPen

Actemra Subcutaneous Injection

 

 

229C

Tolvaptan

Jinarc